Research and Clinical Trials

Title  
TG Therapeutics UTX-TGR-205: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 and TGR-1202 alone in Patients with Previously Treated Diffuse Large B-Cell Lymphoma (UNITY Lymphoma)
Brief Description  
Primary: To assess the efficacy of TGR-1202 alone and in combination with ublituximab in patients with previously treated DLBCL measured by overall response rate (ORR). Secondary: Assess efficacy of TGR-1202 alone and in combination with ublituximab in patiets with previously treated DLBCL as measured by progression free survival (PFS) at month 6.
Who may be Eligible  
Please contact us for eligibility criteria.
Speciality/Disorder  
Non-Hodgkin's Lymphoma
Status  
OPEN
Start Date  
01/26/2017
IRB Number  
00017494
Principal Investigator  
Ghosh, Nilanjan
Contact Name  
Leslie Walker

For More Information, Contact  Leslie  , Walker
Phone:  980-442-2033 Fax:    
Email:  Leslie.Walker@carolinashealthcare.org
Address:1021 Morehead Medical Drive Suite 2200 Charlotte, 28204
Close